All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Acute graft versus host disease (aGvHD) is often a complication of allogenic hematopoietic stem cell transplantation (allo-HSCT). Inflammatory monocytes have shown clinical significance in the pathogenesis of numerous inflammatory diseases, whereby organ infiltration by monocytes may be correlated with the severity of aGvHD. Therefore, targeting inflammatory monocytes may present a new option for the treatment of aGvHD.
On Wednesday 27 March 2019, Oral Session 10 (OS10) took place at the 45th Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT), Frankfurt, DE. During that session, Abstract OS10-3 was presented by John Galvin from the University of Illinois Chicago, IL, United States, discussed whether clinical symptoms and mortality may reduce with the administration of IMPs in murine models of aGvHD.
Dr. Galvin explained that biodegradable micro-particles derived from polymers such as poly(lactic-co-glycolic) acid (PLGA), have been shown to be taken up by inflammatory monocytes. These immune-modifying micro-particles (IMPs) divert monocytes from the site of inflammation, instead, they fuse with monocytes and cause apoptotic cell clearance via the spleen.
Murine aGvHD model:
IMP treatment:
In vivo bioluminescence imaging:
Dr. Galvin concluded the session by demonstrating that in murine models, IMPs significantly reduced symptoms and mortality of aGvHD while preserving the graft-versus-tumor effect (GVT). The model also demonstrated a reduction in circulating inflammatory monocytes, as well as a reduction in hepatic lymphocyte infiltration and intestinal mucosal denudation. Dr. Galvin highlighted the potential of using IMP therapy for inhibiting inflammatory monocyte-mediated pathology in aGvHD.
Subscribe to get the best content related to GvHD delivered to your inbox